Gelesis Holdings, Inc. GLS
We take great care to ensure that the data presented and summarized in this overview for GELESIS HOLDINGS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GLS
View allLatest Institutional Activity in GLS
Top Purchases
Top Sells
About GLS
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Insider Transactions at GLS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 21
2022
|
Raju S Kucherlapati |
BUY
Open market or private purchase
|
Direct |
92,000
+32.59%
|
$0
$0.45 P/Share
|
|
Nov 18
2022
|
Raju S Kucherlapati |
BUY
Open market or private purchase
|
Direct |
8,000
+7.53%
|
$0
$0.39 P/Share
|
|
Jun 15
2022
|
Raju S Kucherlapati |
BUY
Open market or private purchase
|
Direct |
24,625
+21.43%
|
$24,625
$1.95 P/Share
|
|
Jun 08
2022
|
Elaine Chiquette Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
80,500
+23.43%
|
-
|
|
May 06
2022
|
Alison Bauerlein Director |
BUY
Grant, award, or other acquisition
|
Direct |
51,095
+50.0%
|
-
|
|
May 06
2022
|
Kathryn Cavanaugh Director |
BUY
Grant, award, or other acquisition
|
Direct |
48,814
+44.19%
|
-
|
|
May 06
2022
|
David Abraham General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
256,437
+48.84%
|
-
|
|
May 06
2022
|
Elaine Chiquette Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
182,579
+47.41%
|
-
|
|
May 06
2022
|
Clayton Christopher Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,270
+8.8%
|
-
|
|
May 06
2022
|
Paul R. Fonteyne Director |
BUY
Grant, award, or other acquisition
|
Direct |
53,832
+50.0%
|
-
|
|
May 06
2022
|
Raju S Kucherlapati |
BUY
Grant, award, or other acquisition
|
Direct |
50,639
+43.55%
|
-
|
|
May 06
2022
|
Harry L. Leider Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
314,090
+46.58%
|
-
|
|
May 06
2022
|
Elliot Maltz Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
431,975
+48.02%
|
-
|
|
May 06
2022
|
David A. Pass Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
483,219
+46.9%
|
-
|
|
May 06
2022
|
Dominic Perks Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,270
+50.0%
|
-
|
|
May 06
2022
|
Alessandro Sannino Lead Project Scientist |
BUY
Grant, award, or other acquisition
|
Direct |
68,966
+24.98%
|
-
|
|
May 06
2022
|
Jane Wildman Director |
BUY
Grant, award, or other acquisition
|
Direct |
50,182
+50.0%
|
-
|
|
May 06
2022
|
Yishai Zohar President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
960,893
+13.23%
|
-
|
|
Jan 14
2022
|
Raju S Kucherlapati |
BUY
Open market or private purchase
|
Direct |
15,000
+50.0%
|
$90,000
$6.67 P/Share
|
|
Jan 13
2022
|
Kathryn Cavanaugh Director |
BUY
Other acquisition or disposition
|
Direct |
12,825
+50.0%
|
-
|